F-star Therapeutics, Inc.
News
Maven Securities LTD Reduces Stock Position in F-star Therapeutics, Inc. (NASDAQ:FSTX)
Zolmax Maven Securities LTD lowered its stake in F-star Therapeutics, Inc. (NASDAQ:FSTX Get Rating) by 57.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 48,901 shares of the companys stock after selling 64,958 shares during the period. Maven Securities LTDs holdings in F-star ...\n more…
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?\n\n Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.13 per share versus the ...\n more…
invoX Pharma completes acquisition of F-star Therapeutics for $161m
Pharmaceutical Business Review F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.\nThe post invoX Pharma completes acquisition of F-star Therapeutics for $161m appeared first on Pharmaceutical Business review...\n more…
F-star Therapeutics Sees Unusually Large Options Volume (NASDAQ:FSTX)
Ticker Report F-star Therapeutics, Inc. (NASDAQ:FSTX Get Rating) was the recipient of some unusual options trading activity on Tuesday. Stock investors purchased 6,611 call options on the company. This is an increase of 446% compared to the average daily volume of 1,210 call options. Institutional Trading...\n more…
F-star Therapeutics Sees Unusually Large Options Volume (NASDAQ:FSTX)
Zolmax F-star Therapeutics, Inc. (NASDAQ:FSTX Get Rating) was the recipient of some unusual options trading activity on Tuesday. Stock investors purchased 6,611 call options on the company. This is an increase of 446% compared to the average daily volume of 1,210 call options. Institutional Trading of F-...\n more…
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
Business Wire invoX Pharma Limited (invoX), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (Sino Biopharm) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. (F-star...\n more…